GENE EXPRESSION SUPPRESSION AGENTS

RELATED APPLICATION

This application claims the benefit of priority of provisional application No. 60/377,964 filed May 7, 2002.

BACKGROUND OF THE INVENTION

1.Technical Field

The present invention relates to medicine and biomedical research. More specifically, the present invention relates to expression systems to produce small hairpin RNAs (shRNAs) or interfering RNAs (siRNAs), collectively called siRNA in this application, in eukaryotic cells and methods for expressing siRNAs in eukaryotic cells. The present invention also relates to the use of the expression systems as medicinal products.

2. Related Art

RNA interference (RNAi) is a process of sequence-specific, post-transcriptional gene silencing (PTGS) in animals and plants initiated by double-stranded RNA (dsRNA) that is homologous to the silenced gene. It is an evolutionarily conserved phenomenon and a multi-step process that involves generations of active siRNAs in vivo through the action of a mechanism that is not fully understood. RNAi has been used as a reverse genetic tool to study gene function in multiple model organisms, such as plants, *Caenorhabditis elegants* and *Drosophila*, where large dsRNAs efficiently induce gene-specific silencing.

In mammalian cells dsRNAs, 30 base pairs or longer, can activate antiviral response, leading to the nonspecific degradation of RNA transcripts and a general shutdown of host cell protein translation. As a result, the long dsRNA is not a general method for silencing specific genes in mammalian cells.

Recently, various siRNAs that were synthesized chemically or generated biologically using DNA templates and RNA polymerases have been used to down regulate expression of targeted genes in cultured mammalian cells. Among approaches used, it is highly desirable to use DNA constructs that contain promoters of transcriptions and templates for siRNAs to generate siRNAs in vivo and in vitro. Though several different promoters have been adapted in such DNA constructs, types of promoters used remain limited to, Type III RNA polymerase III (Pol III) promoters, such as the U6 promoter and the H1 promoter, and promoters that require viral RNA polymerases, such as the T7 promoter. The present invention provides methods and designs to produce gene expression suppression agents that greatly expand potential usages of siRNAs.

SUMMARY OF THE INVENTION

The present invention relates to methods to produce gene expression suppression agents for expression of siRNAs in mammalian cells. Such agents contain RNA polymerase III (Pol III) transcription promoter elements, template sequences for siRNAs, which are to be transcribed in host cells, and a terminator sequence.

The promoter is any native or engineered transcription promoter. As examples of such promoters (not intended on being limiting), in one embodiment, the promoter is a Type I Pol III promoter, while in another embodiment, the promoter is a combination of Type I Pol III promoter elements and Type III Pol III promoter elements. In other embodiments other types of promoters are present.

The targeted region of siRNA is anywhere on a transcript of any sequence in eukaryotic or viral genomes. The terminator is any native or engineered sequence that terminates the transcription by Pol III or other types of RNA polymerases.

Such gene expression suppression agents are delivered into eukaryotic cells, including (but not limiting to) mammals, insects, worms and plants, with any routes, procedures or methods, such as (but not limited to), in vivo, in vitro, ex vivo, electroporations, transfections or viral vector transduction.

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1 is a schematic representation of the embodiment for generating siRNA in mammalian cells using vertebrate Type I Pol III promoters. Specifically, Fig. 1 is a schematic representation of strategy for generating siRNA in mammalian cells using vertebrate Type I Pol III promoters (5S rRNA gene promoter and others). "A Box", "C Box", "D Box" and "IE" are Pol III promoter elements, "+1" is an initiation site of transcription, "Tn" is a termination site of the Pol III promoter transcript, and the arrow indicates the orientation of transcription. The siRNA template consists of sense,

3

spacer, antisense and terminator sequences, and generates a hairpin dsRNA when expressed. "Sense" is a 17-23 nucleotide (nt) sense sequence that is identical to that of the target gene and is a template of one strand of the stem in the hairpin dsRNA. "Spacer" is a 4-15 nt sequence and is a template of the loop of the strand of the stem in the hairpin dsRNA. "Terminator" is the transcriptional termination signal of five thymidines (5 Ts).

Fig. 2 is a schematic representation of the embodiment for generating siRNA in mammalian cells using vertebrate Type III Pol III promoters (U6 gene promoter, H1 RNA gene promoter, Y1 gene promoter, Y3 gene promoter, RNase P gene promoter and others). DSE, distal sequence element of Pol III promoter: PSE, proximal sequence element of Pol III promoter; TATA, a promoter element; +1, initiation site of transcription; the arrow indicates the orientation of transcription; siRNA Template, a 43 – 66 nt engineered insert that is the template for generating a hairpin dsRNA against a target gene; Sense, a 17 – 23 nt sense sequence from the target gene, template of one strand of stem in the hairpin; Spacer, a 4 – 15 nt sequence, template of loop of the hairpin; Antisense, a 17 – 23 nt antisense sequence, template of the other strand of stem in hairpin; Terminator, the transcriptional termination signal of 5 thymidines (5 Ts).

Fig. 3 is a schematic representation of the embodiment for generating siRNA in mammalian cells using an engineered Pol III promoter containing the elements in both Type I and Type III promoters. "DSE" is a distal sequence element of Type III Pol III promoter. "PSE" is a proximal sequence element of Type III Pol III promoter; "TATA" is

a Type III Pol III promoter element. "A Box," "C Box" and "IE" are Type I Pol III promoter

elements. "+1" is an initiation site of transcription. "Tn" is a termination site of the Type

III Pol III promoter transcript. The arrow indicates the orientation of transcription. The

siRNA template consists of sense, spacer, antisense and terminator sequences, and

generates a hairpin dsRNA when expressed. "Sense" is a 17-23 nt sense sequence

that is identical to that of the target gene and is a template of one strand of the stem in

the hairpin dsRNA. "Spacer" is a 4-15 nt sequence and is a template of the loop of the

hairpin dsRNA. "Antisense" is a 17-23 nt antisense sequence and is a template of the

other strand of stem in hairpin dsRNA. "Terminator" is the transcriptional termination

signal of five thymidines (5 Ts).

Fig. 4 is a schematic representation of the embodiment for generating siRNA in

mammalian cells using two vertebrate Type I Pol III promoters that drive transcriptions

of sense siRNA and antisense siRNA separately. "A Box", "C Box", "D Box" and "IE"

are Pol III promoter elements. "+1" is an initiation site of transcription. "Tn" is a

termination site of the Pol III promoter transcript. The arrow indicates the orientation of

transcription. "Sense siRNA Template" is a 22-28 nt engineered insert that is the

template for generating a sense single-stranded RNA (ssRNA) against a target gene,

and consists of sense and terminator sequences. "Antisense siRNA Template" is a 22-

28 nt engineered insert that is the template for generating an antisense ssRNA against

a target gene, and consists of antisense and terminator sequences. "Sense" is a 17-23

nt sense sequence that is identical to that of the target gene and is a template of one

strand of the stem in the hairpin dsRNA. "Spacer" is a 4-15 nt sequence and is a

template of loop of hairpin dsRNA. "Antisense" is a 17-23 nt antisense sequence and is a template of the other strand of the stem in the hairpin dsRNA. "Terminator" is the transcriptional termination signal of five thymidines (5 Ts).

Fig. 5 is a schematic representation of the embodiment for generating siRNA in mammalian cells using an engineered T7 polymerase and T7 promoter. "Promoter" is a constitutive or context-dependent promoter such as an inducible promoter or a cell type specific promoter; "T7 Polymerase Gene" is a sequence coding for T7 polymerase. T7 promoter is a T7 promoter. "+1" is an initiation site of transcription. The arrow indicates the orientation of transcription. The siRNA template consists of sense, spacer, antisense and terminator sequences, and generates a hairpin dsRNA when expressed. "Sense" is a 17-23 nt sense sequence that is identical to that of the target gene and is a template of one strand of the stem in the hairpin dsRNA. "Spacer" is a 4-15 nt sequence and is a template of the loop of the hairpin dsRNA. "Antisense" is a 17-23 nt antisense sequence and is a template of the other strand of stem in the hairpin dsRNA. "Terminator" is an engineered terminator for T7 polymerase.

Fig. 6 is a schematic representation of the embodiment for generating multiple siRNAs in mammalian cells using a single multiple transcription unit construct. "Unit" is a transcription unit that contains a vertebrate Type I Pol III promoter and a siRNA template. "A Box", "C Box", "D Box" and "IE" are Pol III promoter elements. "+1" is an initiation site of transcription. "Tn" is a termination site of the Pol III promoter transcript. The arrow indicates the orientation of transcription. The structure of siRNA template

consists of sense, spacer, antisense and terminator sequences, and is an engineered

insert that is the template for generating a hairpin dsRNA against a target gene.

"Sense" is a 17-23 nucleotide (nt) sense sequence that is identical to that of the target

gene and is a template of one strand of the stem in the hairpin dsRNA. "Spacer" is a 4-

15 nt sequence and is a template of the loop of the hairpin dsRNA. "Antisense" is a 17-

23 nt antisense sequence and is a template of the other strand of stem in hairpin

dsRNA. "Terminator" is the transcriptional termination signal of five thymidines (5 Ts).

The multiple siRNAs may target a single region on one gene, different regions on one

gene, or one region on each of many genes.

DETAILED DESCRIPTION OF THE INVENTION

The following detailed description is provided to aid those skilled in the art to use the

present invention. It should not be viewed as defining limitations of this invention.

The present invention is directed to selectively suppress expression of genes targeted

within mammalian cells by making and using DNA constructs that contains RNA

polymerase III (Pol III) transcription promoter elements, template sequences for siRNAs,

which are to be transcribed in host cells, and a terminator sequence.

The promoter is any native or engineered transcription promoter. In one embodiment,

the promoter is a Type I Pol III promoter. The essential elements of Type I promoter,

such as "A Box", "C Box", "D Box" and "IE" are included in the DNA construct. In this

embodiment, siRNA template is arranged between the "D Box" and "A Box". As in

7

another embodiment, the promoter is a combination of Type I Pol III promoter elements

and Type III Pol III promoter elements. In this embodiment, the essential elements of

both types of promoters, such "A Box", "C Box", and "IE" of Type I promoter, as well as

"DSE", "PSE" and "TATA" of Type III promoter are included in the DNA construct, with

"DSE", "PSE" and "TATA" in the upstream region of "+1" position, "A Box", "C Box", and

"IE" in the down stream region of the "+1" position. Any promoter that is functioned in

the mammalian cells is suitable to be used in this invention. Modifications, such as

adding inducible or enhancing elements to exiting promoters, is suitable to be used in

this invention.

The targeted region of siRNA is anywhere on a transcript of any sequence in

mammalian or viral genomes. In some embodiments, templates for siRNA code for

RNA molecules with "hairpin" structures contains both sense and antisense sequences

of targeted genes. In other embodiments, the template for sense sequence and the

template for antisense sequences are driven by different promoters.

The terminator is any native or engineered sequence that terminates the transcription

by Pol III or other types of RNA polymerases, such as, without limited to, a stretch of 4

or more thymidines (T) residues in a DNA molecule.

Any transcriptional unit containing a promoter, a template for RNA and a terminator, is

suitable to be constructed with one other unit, or multiple units, in a DNA molecule as an

agent. In one embodiment, a multiple units construct is showed. More than one kind of

the gene expression suppression agents (DNA molecules) are suitable to be introduced

into mammalian cells together. The siRNAs generated within the same mammalian cell

by these multiple units or co-introduction approaches provide agents ability to target one

specific region in one targeted RNA molecule, multiple regions in one targeted RNA

molecule, or multiple regions in more than one RNA molecules.

Such DNA constructs as indicated above can be constructed as a part of any suitable

cloning vectors or expression vectors. Then the agents can be delivered into cells,

tissues or organisms with any routes, procedures or methods, such as in vivo, in vitro,

ex vivo, injection, electroporations, transfections or viral vector transduction.

EXAMPLES

Example 1

Cloning of the human 5S rDNA regulatory sequences.

The promoter chosen for the experimental design proposed below is the human 5S

rRNA gene. The sequence is available in the database: Genbank Accession Number

X12811. 5S rRNA promoter contains downstream Boxes A and C and upstream Box D.

In Fig. 1, the 49 nt sequence between the initiation site of the 5S rRNA and Box A is

proposed to be replaced with interfering RNA sequence. Generation of a cassette

containing both upstream and downstream boxes will be carried out in two steps.

Cloning of the Box A and C can be achieved by chemical synthesis. The upstream Box

D is done by PCR.

Cloning of the recombinant 5S rDNA Box D is carried out through PCR using forward

primer (AACggatccaaaacgctgcctccgcga) and reverse primer

(TAGACGCTGCAGGAGGCGCCTGGCT, which can then be subcloned into BamHI and

PstI sites of pBS2SK. The Box A/C can be synthesized as top strand

(AGAAGACGAagctaagcagggtcgggcctggttagtacttggatgggagaccgcctgggaataccgggtgctgta

ggctttttg) and bottom strand

(TCGACAAAAAGCCTACAGCACCCGGTATTCCCAGGCGGTCTCCCATCCAAGTACT

AACCAGGCCCGACCCTGCTTAGCTTCGTCTTCT), which are then annealed and

subcloned into EcoRV and SalI sites downstream of the cloned Box D. The annealed

DNA fragment is engineered with a BbsI site.

Example 2

Insertion and Cloning of RNAi Sequence.

The RNAi cassette will be synthesized as two strands and cloned between PstI and

BbsI site. The RNAi cassette is designed as follows:

      5' GC(N19)TTTCGG(61N)TTTTT 3'

      3' ACGTCG(61N)AAAGCC(N19)AAAAATCGA 5'

N19 is the 19 nt target DNA sequence selected from the transcribed region of a target

gene. 61N is the reverse and complementary strand of N19. Transcription is initiated

from the first base of N19 target sequence and terminated at the poly T.

Example 3

Targeting ErbB2/Her2 in breast cancers.

ErbB2/Her2 gene is amplified in ~30% of breast cancers in human, causing fast growth and metastasis of cancer cells. Herceptin, an antibody made by Genentech that blocks ErbB2 functions, is the only agent used by ErbB2-positive breast cancer patients that slows progression of metastatic breast disease and increases overall survival for patients given the drug along with standard chemotherapy compared to chemotherapy alone. Generation of siRNAs targeting ErbB2 developed with this invention should provide an alternative treatment.

Example 4

Targeting BCR-Abl tyrosine kinase in chronic myelogenous leukemia (CML) and other cancers. BCR-Abl is a fusion gene product that frequently occurs in CML. STI571, also called Gleevec developed by Novartis, is newly approved anticancer agent to target BCR-Abl in CML. Generation of siRNAs against the fusion gene BCR-Abl, without interfering with the normal expression of either BCR or Abl gene, developed with this invention should have great potential for gene therapy to treat CML.

Example 5

Targeting Hepatitis B Virus (HBV).

Using this invention to target different sites of the HBV genome will provide a potent gene therapy to treat hepatitis B infected patients.

Example 6

Targeting Human Immunodeficiency Virus Type 1 (HIV-1).

Using this invention to target different sites of the HIV genome will provide a potent

gene therapy for HIV infected patients. A multiple units agent simultaneously targeting

multiple sites, such as env, gag, pol, vif, nef, vpr, vpu and tat, may be suitable to

address resistances resulted from mutations of HIV genome.